Head-To-Head Survey: Prana Biotechnology (PRAN) & Yield10 Bioscience (YTEN)

Yield10 Bioscience (NASDAQ: YTEN) and Prana Biotechnology (NASDAQ:PRAN) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Yield10 Bioscience and Prana Biotechnology, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yield10 Bioscience 0 0 0 0 N/A
Prana Biotechnology 0 0 1 0 3.00

Prana Biotechnology has a consensus price target of $4.00, indicating a potential upside of 58.10%. Given Prana Biotechnology’s higher probable upside, analysts plainly believe Prana Biotechnology is more favorable than Yield10 Bioscience.

Earnings & Valuation

This table compares Yield10 Bioscience and Prana Biotechnology’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Yield10 Bioscience $1.16 million 11.24 -$7.60 million ($2.95) -0.52
Prana Biotechnology $2.37 million 9.50 -$5.68 million N/A N/A

Prana Biotechnology has higher revenue and earnings than Yield10 Bioscience.

Profitability

This table compares Yield10 Bioscience and Prana Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Yield10 Bioscience -743.10% -214.42% -109.09%
Prana Biotechnology N/A N/A N/A

Risk & Volatility

Yield10 Bioscience has a beta of 3.43, suggesting that its share price is 243% more volatile than the S&P 500. Comparatively, Prana Biotechnology has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500.

Insider & Institutional Ownership

4.8% of Yield10 Bioscience shares are held by institutional investors. Comparatively, 1.9% of Prana Biotechnology shares are held by institutional investors. 11.2% of Yield10 Bioscience shares are held by insiders. Comparatively, 38.8% of Prana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Prana Biotechnology beats Yield10 Bioscience on 8 of the 11 factors compared between the two stocks.

Yield10 Bioscience Company Profile

Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.

Prana Biotechnology Company Profile

Prana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders. The Company’s lead product candidates are PBT2 and PBT434. The Company’s lead drug candidate PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases. The Company also has advanced a drug candidate for Parkinson’s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply